Budesonide/formoterol

application：Salermide was used to treat human pulmonary artery smooth muscle cells to study the effect of SIRT1 inhibition on expression of atrogin by qPCR.

sPLA2 inhibitor is a potent secretory Phospholipase A2 (sPLA2: Group IIa) inhibitor. The compuond is also a potent antiinflammatory agent and apoptosis inducer of lung cancer cells.

sPLA2 inhibitor is a potent secretory Phospholipase A2 (sPLA2: Group IIa) inhibitor. The compuond is also a potent antiinflammatory agent and apoptosis inducer of lung cancer cells.

InformationVilanterol trifenatate (GW642444M) is a novel inhaled long-actingbeta2 adrenoceptoragonist with inherent 24-hour activity for once daily treatment of COPD and asthma.Targetsβ2-adrenoceptorIn vitroVilanterol displays a subnanomolar

InformationVilanterol trifenatate (GW642444M) is a novel inhaled long-actingbeta2 adrenoceptoragonist with inherent 24-hour activity for once daily treatment of COPD and asthma.Targetsβ2-adrenoceptorIn vitroVilanterol displays a subnanomolar

InformationVilanterol trifenatate (GW642444M) is a novel inhaled long-actingbeta2 adrenoceptoragonist with inherent 24-hour activity for once daily treatment of COPD and asthma.Targetsβ2-adrenoceptorIn vitroVilanterol displays a subnanomolar

InformationVilanterol trifenatate (GW642444M) is a novel inhaled long-actingbeta2 adrenoceptoragonist with inherent 24-hour activity for once daily treatment of COPD and asthma.Targetsβ2-adrenoceptorIn vitroVilanterol displays a subnanomolar

InformationVilanterol trifenatate (GW642444M) is a novel inhaled long-actingbeta2 adrenoceptoragonist with inherent 24-hour activity for once daily treatment of COPD and asthma.Targetsβ2-adrenoceptorIn vitroVilanterol displays a subnanomolar

A cell-permeable, selective inhibitor of N-WASP (IC₅₀ = ~ 10 &muM) directly associates with the GTPase-binding domain of N-WASP, preventing its activation by Cdc42 and PIP2 interferes with membrane transport, endocytosis, and